There was a study presented at the American Urology Assoc meeting 2
years ago and published last year showing that TUNA was no better than
sham treatment in improving symptoms of type III prostatitis.

Urology. 2002 Aug;60(2):300-4.
 
Transurethral needle ablation for the treatment of chronic pelvic pain
syndrome (category III prostatitis): a randomized, sham-controlled
study.

Leskinen MJ, Kilponen A, Lukkarinen O, Tammela TL.

Department of Surgery/Urology, Seinajoki Central Hospital, Seinajoki,
Finland.

OBJECTIVES: To investigate the effectiveness and durability of
transurethral needle ablation (TUNA) in the treatment of symptoms of
chronic pelvic pain syndrome (CPPS) in a randomized, single-blind,
sham-controlled study. METHODS: Thirty-three patients with
moderate-to-severe symptoms of CPPS were randomized to either TUNA (n
= 25) or urethrocystoscopy as a sham treatment (n = 8). The response
to therapy was evaluated 3, 6, and 12 months after treatment using the
Prostatitis Symptom Severity Index (PSSI), the International Prostate
Symptom Score (IPSS), a visual analogue scale, and prostate volume,
prostate-specific antigen, urinary flow, and residual urine volume
measurements. RESULTS: The PSSI decreased in both groups (TUNA group,
P <0.001; sham group, P not significant), but no statistically
significant difference was detected between them. Similarly, the IPSS
decreased in the two groups (TUNA group, P = 0.002; sham group, P =
0.05), but no difference was found between those treated with TUNA and
those who underwent sham treatment. Also the quality of life (IPSS-8)
was significantly better at 12 months in both groups, but no
difference was detected between them. Changes in pain score (visual
analogue scale) were not statistically significant. Peak urinary flow
rate, residual urine volume, prostate-specific antigen, and prostate
volume were not altered in either group. CONCLUSIONS: The efficacy of
TUNA in CPPS is comparable to sham treatment, and so cannot be
recommended as routine treatment of CPPS.